drugset

drugset / Trial / NCT03005262

MLN8237 for a Subject With Adenocarcinoma of the Prostate

NCT03005262 ↗

Expanded access No longer available The University of Texas Health Science Center at San Antonio

Summary

To allow a patient continued access to MLN8237

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Alisertib	Small molecule	—	—

Indications